跳到主要內容

臺灣博碩士論文加值系統

(3.236.124.56) 您好!臺灣時間:2021/07/28 08:44
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果 :::

詳目顯示

我願授權國圖
: 
twitterline
研究生:許綺娟
研究生(外文):Chi-Chang Hsu
論文名稱:Digoxin血中有效治療濃度範圍之評估
論文名稱(外文):To Evaluate Digoxin Therapeutic Range
指導教授:林双金林双金引用關係
指導教授(外文):Shun-Jin Lin
學位類別:碩士
校院名稱:高雄醫學大學
系所名稱:藥學研究所碩士在職專班
學門:醫藥衛生學門
學類:藥學學類
論文種類:學術論文
論文出版年:2005
畢業學年度:93
語文別:中文
論文頁數:61
中文關鍵詞:鬱血性心衰竭毛地黃血中治療濃度監測
外文關鍵詞:congestive heart failureDigoxinTherapeutic Drug Monitoring
相關次數:
  • 被引用被引用:0
  • 點閱點閱:498
  • 評分評分:
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:0
本研究的目的在評估毛地黃(digoxin)血中濃度之分佈資料與臨床反應探討;以回溯性方式收集資料,來自高雄榮民總醫院在西元2003年一月至2003年十二月中一整年內172位住院及急診病患之digoxin藥物治療濃度監測報告並配合回顧病歷,且以描述性統計方式探討其統計量,依變相為藥物血中濃度,而探討之自變相包括性別、疾病、藥物交互作用、腎功能,並介定藥物治療濃度不足、治療濃度足夠及治療濃度過高有毒性反應時這三者間不同,且分別以平均值,標準誤差,以及95% 信賴區間來表示。將使用SPSS 12.0作統計分析。
The aim of this study was to evaluate the distribution of serum digoxin concentration and clinical outcome. By using a cross- sectional and retrospective studies to investigate the data from 172 patients of Kaohsiung Veterans General Hospital from January 2003 to December 2003, which were monitored the serum digoxin concentration reports and double checked by their charts. The dependent examined was serum digoxin concentration and the independent variables were sex, disease status, co-morbidities and laboratory examinations, respectively. Finally the study was to find out the therapeutic range of serum digoxin concentration according to their sub-, within- and supra-therapeutic range respectively, and denoted as mean, standard error and 95% confidence interval. All the statistical work were performed using SPSS 12.0 Base.
中文摘要 ---------------------------------------------------------------- 1
英文摘要 ---------------------------------------------------------------- 2
研究目的 ---------------------------------------------------------------- 3
第一節 緒論 ------------------------------------------------------------ 4
壹、背景資料 ---------------------------------------------------5
貳、Digoxin治療濃度 -------------------------------------------14
參、國內外對藥物治療監測之研究方向 ----------------------------19
第二節 研究方法 -------------------------------------------------------29
第三節 結果與討論 -----------------------------------------------------32
第四節 結論 -----------------------------------------------------------42
附表 -------------------------------------------------------------------44
附圖 -------------------------------------------------------------------54
參考文獻 ---------------------------------------------------------------59
1.Campbell TJ, MacDonald PS. Digoxin in heart failure and cardiac arrhythmias. MJA. 2003 Jul 21;179(2):98-102.

2.Sameri RM, Soberman JE, Finch CK, Self TH. Lower serum digoxin concentrations in heart failure and reassessment of laboratory report forms. Am J Med Sci. 2002 Jul;324(1):10-3.

3.Spencer AP. Digoxin in heart failure. Crit Care Nurs Clin North Am. 2003 Dec;15(4):447-52.

4.Rahimtoola SH. Digitalis therapy for patients in clinical heart failure. Circulation. 2004; 109: 2942-2946.

5.Abernethy DR, Greenblatt DJ: Pharmacokinetics of drugs in obesity. Clin Pharmacokinet. 1982 Mar-Apr;7(2):108-24.

6.Haji SA, Movahed A. Update on digoxin therapy in congestive heart failure. Am Fam Physician. 2000 Jul 15;62(2):409-16.

7.陳柳文,鬱血性心衰竭治療digoxin的使用,秀傳藥刊 八十九年三月十五日出版第五卷 第一期

8.Digoxin in the 21st century. Aust Prescr. 1999;22:136-7

9.Matzuk MM, Shlomchik M, Shaw LM. Making digoxin therapeutic drug monitoring more effective. Ther Drug Monit. 1991 May;13(3):215-9.

10.Barclay M, Begg E. The practice of digoxin therapeutic drug monitoring. N Z Med J. 2003 Dec 12;116(1187):U704.

11.Mordasini MR, Krahenbuhl S, Schlienger RG. Appropriateness of digoxin level monitoring. Swiss Med Wkly. 2002 Sep 7;132(35-36):506-12.

12.Mason GD, Winter ME. Appropriateness of sampling times for therapeutic drug monitoring. Am J Hosp Pharm. 1984 Sep; 41 (9): 1796-801.

13.Frisolone J, Sylvia LM, Gelwan J, Pal S, Pellechia C. False-positive serum digoxin concentrations determined by three digoxin assays in patients with liver disease. Clin Pharm. 1988 Jun;7(6):444-9.

14.Sidwell A, Barclay M, Begg E, Moore G. Digoxin therapeutic drug monitoring: an audit and review. N Z Med J. 2003 Dec 12;116(1187):U708.

15.The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997; 336: 525-533.

16.Uretsky BF, Young JB, Shahidi FE, Yellen LG, Harrison MC, Jolly MK. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group. J Am Coll Cardiol. 1993; 22: 955-962.

17.Packer M, Gheorghiade M, Young JB, Costantini PJ, Adams KF, Cody RJ, Smith LK, Van Voorhees L, Gourley LA, Jolly MK. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. N Engl J Med. 1993; 329: 1-7.

18.Clague HW, Twum-Barima Y, Carruthers SG. An audit of requests for therapeutic drug monitoring of digoxin: problems and pitfalls. Ther Drug Monit. 1983;5(3):249-54.

19.Bernard DW, Bowman RL, Grimm FA, Wolf BA, Simson MB, Shaw LM. Nighttime dosing assures postdistribution sampling for therapeutic drug monitoring of digoxin. Clin Chem. 1996 Jan;42(1):45-9.

20.Riaz K, Forker AD. Digoxin use in congestive heart failure. Current status. Drugs. 1998 Jun;55(6):747-58.

21.Canas F, Tanasijevic MJ, Ma''luf N, Bates DW. Evaluating the appropriateness of digoxin level monitoring. Arch Intern Med. 1999 Feb 22;159(4):363-8.

22.Terra SG, Washam JB, Dunham GD, Gattis WA. Therapeutic range of digoxin''s efficacy in heart failure: what is the evidence? Pharmacotherapy. 1999 Oct;19(10):1123-6.

23.Tuncok Y, Hazan E, Oto O, Guven H, Catalyurek H, Kalkan S. Relationship between high serum digoxin levels and toxicity. Int J Clin Pharmacol Ther. 1997 Sep;35(9):366-8.

24.Bonagura E, Law T, Rifai N. Assessment of the immunoreactivity of digoxin metabolites and the cross-reactivity with digoxin-like immunoreactive factors in the Roche-TDM ONLINE digoxin assay. Ther Drug Monit. 1995 Oct;17(5):532-7.

25.Lewis RP. Clinical use of serum digoxin concentrations. Am J Cardiol. 1992 Jun 4;69(18):97G-106G; discussion 106G-107G.

26.Howanitz PJ, Steindel SJ. Digoxin therapeutic drug monitoring practices. A College of American Pathologists Q-Probes study of 666 institutions and 18,679 toxic levels. Arch Pathol Lab Med. 1993 Jul;117(7):684-90.

27.Dobbs RJ, Nicholson PW, Denham MJ, Dobbs SM, O''Neill CJ. Therapeutic drug monitoring of digoxin: help or hindrance? Eur J Clin Pharmacol. 1986;31(4):491-5.

28.Demers C, McKelvie RS, Yusuf S. The role of digitalis in the treatment of heart failure. Coron Artery Dis. 1999 Sep;10(6):353-60.

29.Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA. 2003 Feb 19;289(7):871-8.
QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top